Managing hot flashes in men being treated for prostate cancer

Prostate cancer is the most common malignancy in men. Treatment with hormonal ablation is often accompanied by disabling hot flashes. This article reviews the pathophysiology of hot flashes and treatment options for this common side effect of treatment.

Saved in:

Bibliographic Details
Published in:	Geriatrics Vol. 62; no. 11; p. 18
Main Authors:	Baum, Neil H, Torti, Dorothea C
Format:	Magazine Article
Language:	English
Published:	United States 01-11-2007
Subjects:	Androgen Antagonists - adverse effects Androgen Antagonists - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Combined Modality Therapy Complementary Therapies Cyclohexanols - therapeutic use Diethylstilbestrol - therapeutic use Gonadotropin-Releasing Hormone - agonists Gonadotropin-Releasing Hormone - therapeutic use Hot Flashes - chemically induced Hot Flashes - drug therapy Hot Flashes - physiopathology Humans Male Megestrol Acetate - therapeutic use Orchiectomy Prostatic Neoplasms - drug therapy Prostatic Neoplasms - physiopathology Testosterone - blood Venlafaxine Hydrochloride
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Prostate cancer is the most common malignancy in men. Treatment with hormonal ablation is often accompanied by disabling hot flashes. This article reviews the pathophysiology of hot flashes and treatment options for this common side effect of treatment.
ISSN:	1936-5764